As Zyomyx Rolls Out its Cytokine Arrays, Glaxo Becomes First Pharma to Acquire Early Access | GenomeWeb

Zyomyx made the jump to big pharma last week, signing GlaxoSmithKline as an early access partner as it prepares to commercially launch its protein chip platform early next year. Glaxo is now the third party to gain early access to Zyomyx’s cytokine array and analysis platform, after Specialty Laboratories and Partners Healthcare, the administrator for two Harvard University-associated teaching and research hospitals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.